Self-amplifying mRNA nanovaccine encoding GM-CSF-fused HPV16 E7 enhances immunogenicity and therapeutic efficacy against cervical cancer

Nov 12, 2025International journal of biological macromolecules

A self-boosting mRNA nanovaccine with GM-CSF-linked HPV16 E7 improves immune response and treatment against cervical cancer

AI simplified

mRNA Technology on OpenScience ↗PubMed ↗DOI ↗

Abstract

LPR-saRNA-GM-CSF-E7 vaccination significantly delayed tumor progression and prolonged survival in TC-1 tumor-bearing mice.

Cervical cancer is associated with the malignant transformation of cells by the HPV E7 oncoprotein.
The developed saRNA vaccine encodes either HPV16 E7 or a fusion of GM-CSF with HPV16 E7, both delivered in nanoparticles.
Intramuscular administration in mice resulted in strong immune responses and enhanced T-cell activity.
The LPR-saRNA-GM-CSF-E7 vaccine reprogrammed the tumor environment by decreasing immunosuppressive cells and increasing specific cytokine levels.
In vivo assays showed that LPR-saRNA-GM-CSF-E7 induced significant E7-specific cytotoxic T cell activity.

AI simplified

Cervical cancer, driven by the malignant transformation of keratinocytes via the human papillomavirus (HPV) E7 oncoprotein, remains a significant global health challenge. In this study, we developed an alphavirus-based self-amplifying mRNA (saRNA) vaccine encoding either a genetically engineered HPV16 E7 gene or a fusion of granulocyte-macrophage colony-stimulating factor (GM-CSF) with HPV16 E7, both encapsulated in self-assembling liposome-protamine-RNA (LPR) nanoparticles. SaRNA represents a promising vaccine platform due to its intrinsic ability to amplify and prolong antigen expression, offering a substantial advantage over conventional mRNA approaches. Intramuscular administration of LPR-saRNA-GM-CSF-E7 in mice triggered robust innate immune responses and activated antigen-presenting cells in the draining lymph nodes, leading to enhanced T-cell effector functions. The LPR-saRNA-GM-CSF-E7 nanovaccine more effectively reprogrammed the tumor microenvironment by reducing immunosuppressive cell populations and increasing Th1 cytokine expression compared to LPR-saRNA-E7. Importantly, in vivo cytotoxic T lymphocyte (CTL) assays demonstrated that LPR-saRNA-GM-CSF-E7 vaccination elicited potent E7-specific CD8T cell cytolytic activity. Furthermore, this nanovaccine significantly delayed tumor progression and prolonged survival in TC-1 tumor-bearing mice, underscoring its superior efficacy over the LPR-saRNA nanovaccine encoding only E7. These findings highlight the potential of the LPR-saRNA-GM-CSF-E7 nanovaccine as a novel and promising therapeutic strategy for cervical cancer immunotherapy. +

Full Text

Full text is available at the source.

View full text (XML) ↗View full text ↗

Self-amplifying mRNA nanovaccine encoding GM-CSF-fused HPV16 E7 enhances immunogenicity and therapeutic efficacy against cervical cancer

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the mrna technology brief

Abstract

Full Text

Related papers

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the mrna technology brief